Compare ANNX & CSIQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | CSIQ |
|---|---|---|
| Founded | 2011 | 2001 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.1M | 906.4M |
| IPO Year | 2020 | 2006 |
| Metric | ANNX | CSIQ |
|---|---|---|
| Price | $3.75 | $9.27 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 12 |
| Target Price | $15.43 | ★ $17.01 |
| AVG Volume (30 Days) | ★ 3.4M | 1.6M |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.35 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.54 | $9.05 |
| 52 Week High | $7.18 | $34.59 |
| Indicator | ANNX | CSIQ |
|---|---|---|
| Relative Strength Index (RSI) | 42.75 | 31.38 |
| Support Level | $3.71 | N/A |
| Resistance Level | $4.37 | $16.48 |
| Average True Range (ATR) | 0.24 | 0.54 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 43.65 | 10.94 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Canadian Solar Inc is a Canadian solar technology and renewable energy company. It is a manufacturer of solar photovoltaic modules, a provider of battery energy storage solutions, and a developer of utility-scale solar power and battery energy storage projects. The company is organized in two segments: Manufacturing segment, comprising CS PowerTech, which focuses on manufacturing and sales of solar products, battery energy storage products, and other power technology products for the U.S. market and CSI Solar, which serves all other world-wide markets; and Recurrent Energy segment, which focuses on solar power and battery storage project development, asset sales, power services, and electricity revenue from its operating portfolio. It derives maximum revenue from Manufacturing segment.